Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions.
Chronic diabetes mellitus is associated with various complications such as retinopathy, neuropathy, nephropathy, cardiomyopathy, vasculopathy, dermatopathy and encephalopathy. Nephropathy is one of the major complications of diabetes mellitus, and the morbidity and mortality due to diabetic nephropathy is constantly progressing in industrialized nations. No satisfactory therapeutic option is currently available to treat patients with nephropathy except for fewer agents like angiotensin converting enzyme inhibitors, angiotensin AT(1) receptor blockers and few antioxidants, which have been shown to improve the function of diabetic kidney to some extent. Thus, tremendous efforts are being made to explore promising therapeutic interventions to treat diabetic nephropathy. This review discussed various presently employed and recently developed pharmacological interventions to treat diabetic nephropathy and to improve the function of diabetic kidney. In addition, the recently identified potential target sites involved in the pathogenesis of diabetic nephropathy have been delineated.
Cardiovascular Pharmacology Division, ISF College of Pharmacy, Moga 142001, Punjab, India. pbala2006@gmail.com
Pitchai
P
Balakumar
Mandeep Kumar
MK
Arora
Subrahmanya S
SS
Ganti
Jayarami
J
Reddy
Manjeet
M
Singh
D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D012084:Renin-Angiotensin System / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors
D002121:Calcium Channel Blockers; D017127:Glycation End Products, Advanced; D000451:Mineralocorticoid Receptor Antagonists; D016212:Transforming Growth Factor beta; D011493:Protein Kinase C